The Asthma Market was valued at approximately USD 25 Billion in 2023 and is expected to grow at a strong CAGR of around ~5% during the forecast period (2024-2032) owing to the robust pipeline activity ...

Hyperpolarized xenon MRI may be useful in assessing response to biologic treatment among patients with asthma, according to a ...

AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Discover a study that highlights a potentially critical role for the BDNF-NTRK2 pathway in EoE symptom development.

If you or someone you know has chronic asthma do read this article to know how biologics can potentially help in treating the condition ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American ...

MANCHESTER, England — A soon-to-be-released guidance from the British Society for Rheumatology on the management of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV ...